Europe Neurostimulation Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Europe Neurostimulation Market is Segmented by Technology, Application (Parkinson's Disease, Epilepsy, Depression, Dystonia, Pain Management, and Other Applications), and Geography.

Market Snapshot

Asia Pacific Electrophysiology Market_1
Study Period: 2018 - 2026
Base Year: 2020
CAGR: 6.1 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The major factors for the growth of the European neurostimulation market include the growth in the geriatric population and rising prevalence of neurological disorders, increasing demand for minimally invasive surgeries, and technological advancements.

Among the age-related neurodegenerative disorders, Parkinson’s disease (PD) is the second-most common, after Alzheimer’s disease. According to NHS UK, Parkinson's disease affects around 1 in 500 people. Hence, there are an estimated 127,000 people in the United Kingdom, who are currently living with the condition. Most people with Parkinson's start to develop symptoms when they're over 50, although around 1 in 20 people with the condition, first experience symptoms when they're under 40. Furthermore, neurostimulation devices also play a significant role in pain management. In November 2018, Abbott announced the launch of the new DRG Invisible Trial System, which is approved by the US Food and Drug Administration (FDA) and has received the CE Mark in Europe. Thus, owing to the rising prevalence of neurological diseases and increasing technological advancements, the market is expected to witness high growth over the forecast period.

Scope of the Report

As per the scope of this report, neurostimulation therapies include invasive and noninvasive approaches that involve the application of electrical stimulation, to drive neural function within a circuit. The market is segmented by technology, application, and geography.

Report scope can be customized per your requirements. Click here.

Key Market Trends

Parkinson’s Disease Segment is expected to be the Fastest Growing Segment

With the growing aging population and increasing prevalence of Parkinson's disease, the market is expected to witness a high growth rate. Parkinson's syndrome is one of the most common neurological diseases found in Germany. It is found to be affecting the older population, and among people aged above 65 years, the prevalence is 1,800 per 100,000. Therefore, in Germany, the number of patients is likely to increase in the future. Furthermore, Europe has a growing aging population. For instance, according to the Fondation de France, one in five French person is over 60 years old, and in 2050 one in three will be. Therefore age-associated diseases are assuming ever-greater proportions. Parkinson’s disease currently affects around 150,000 people in France. Deep Brain Stimulation (DBS) is the most commonly performed surgical treatment for Parkinson's, but it's not for everyone. DBS therapy is currently approved in many locations across the world, including the United States and Europe, as a treatment for the disabling symptoms of essential tremors, and recently, the long-standing Parkinson's disease. Thus, owing to the all above-mentioned factors, the market is expected to witness high growth over the forecast period.

Picture1_EU neuro.png

Competitive Landscape

The market studied is a moderately consolidated market, owing to the presence of small and large market players. Some of the market players are Medtronic PLC, Boston Scientific Corporation, Abbott Laboratories, LivaNova PLC, Nevro Corporation, NeuroSigma Inc., The Magstim Company Limited, Neuronetics, and Renishaw PLC.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increase in Geriatric Population and Rising Prevalence of Neurological Disorders

      2. 4.2.2 Rising Demand of Minimally Invasive Surgeries

      3. 4.2.3 Technological Advancements

    3. 4.3 Market Restraints

      1. 4.3.1 Side Effects of Associated Neurostimulation Devices

      2. 4.3.2 Stringent Regulatory Approvals

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Technology

      1. 5.1.1 Internal Neuromodulation

        1. 5.1.1.1 Spinal Cord Stimulation (SCS)

        2. 5.1.1.2 Deep Brain Stimulation (DBS)

        3. 5.1.1.3 Vagus Nerve Stimulation (VNS)

        4. 5.1.1.4 Sacral Nerve Stimulation (SNS)

        5. 5.1.1.5 Gastric Electrical Stimulation (GES)

      2. 5.1.2 External Neuromodulation (Non-Invasive)

        1. 5.1.2.1 Transcutaneous Electrical Nerve Stimulation (TENS)

        2. 5.1.2.2 Transcranial Magnetic Stimulation (TMS)

        3. 5.1.2.3 Respiratory Electrical Stimulation (RES)

    2. 5.2 By Application

      1. 5.2.1 Parkinson's disease

      2. 5.2.2 Epilepsy

      3. 5.2.3 Depression

      4. 5.2.4 Dystonia

      5. 5.2.5 Pain Management

      6. 5.2.6 Other Applications

    3. 5.3 Geography

      1. 5.3.1 Europe

        1. 5.3.1.1 Germany

        2. 5.3.1.2 United Kingdom

        3. 5.3.1.3 France

        4. 5.3.1.4 Italy

        5. 5.3.1.5 Spain

        6. 5.3.1.6 Rest of Europe

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Medtronic PLC

      2. 6.1.2 Boston Scientific Corporation

      3. 6.1.3 Abbott Laboratories

      4. 6.1.4 LivaNova PLC

      5. 6.1.5 Nevro Corporation

      6. 6.1.6 NeuroSigma Inc.

      7. 6.1.7 The Magstim Company Limited

      8. 6.1.8 Neuronetics

      9. 6.1.9 Renishaw PLC

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Europe Neurostimulation Market market is studied from 2018 - 2026.

The Europe Neurostimulation Market is growing at a CAGR of 6.1% over the next 5 years.

Medtronic PLC, Abbott Laboratories, The Magstim Company Limited, Renishaw PLC, Boston Scientific Corporation are the major companies operating in Europe Neurostimulation Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!